eXoZymes (NASDAQ:EXOZ – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
eXoZymes Price Performance
Shares of eXoZymes stock opened at $13.07 on Wednesday. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.01. eXoZymes has a 12 month low of $8.50 and a 12 month high of $23.99. The business has a fifty day simple moving average of $11.62 and a 200 day simple moving average of $11.60.
eXoZymes (NASDAQ:EXOZ – Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter.
eXoZymes Company Profile
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Featured Articles
- Five stocks we like better than eXoZymes
- There Are Different Types of Stock To Invest In
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- How to Invest in the FAANG Stocks
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- What is a Special Dividend?
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Receive News & Ratings for eXoZymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eXoZymes and related companies with MarketBeat.com's FREE daily email newsletter.
